Efficacy and safety of hydroxychloroquine in osteoarthritis: a systematic review and metaanalysis of randomized controlled trials
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Conventional disease-modifying anti-rheumatic drugs have been trialed in osteoarthritis (OA). Hydroxychloroquine (HCQ), which has shown its effectiveness in rheumatoid arthritis, has been trialed for the treatment of OA; however, its efficacy and safety remain unclear. This systematic review and meta-analysis evaluate efficacy and safety of HCQ for the treatment of OA. Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through June 2020. Two reviewers independently screened for randomized controlled trials (RCTs) comparing HCQ with placebo or other active-comparators for the treatment of knee, hand, or hip OA, extracted data, and performed Cochrane risk of bias assessments. Results: Six RCTs, four in hand OA, two in knee OA, consisting of 842 patients (436 in HCQ arm, 406 in control arm) were included. RCTs were conducted between 2012 and 2020, one each at UK, Netherlands, Germany, Italy, Iran, and Egypt; follow-up period ranged 24 to 52 weeks. High-quality evidence showed no clinically important pain reduction with HCQ compared to placebo/active-control in hand OA (standardized mean difference [SMD], 0.14; 95% confidence interval [CI], –0.20 to 0.48). Effect on pain reduction in knee and hand OA was small and non-significant (SMD, –0.09; 95% CI, –0.44 to 0.25). High-quality evidence showed no improvement in dysfunction with HCQ compared to placebo in hand OA patients (SMD, 0.08; 95% CI, –0.23 to 0.40). Effect on dysfunction improvement in knee and hand OA was modest and statistically non-significant (SMD, –0.20; 95% CI, –0.57 to 0.18). No improvement in quality of life was observed in hand OA. Conclusions: HCQ has no benefit in reducing pain and improving physical function in hand or knee OA patients.
Abstract
Background/Aims: Conventional disease-modifying anti-rheumatic drugs have been trialed in osteoarthritis (OA). Hydroxychloroquine (HCQ), which has shown its effectiveness in rheumatoid arthritis, has been trialed for the treatment of OA; however, its efficacy and safety remain unclear. This systematic review and meta-analysis evaluate efficacy and safety of HCQ for the treatment of OA. Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through June 2020. Two reviewers independently screened for randomized controlled trials (RCTs) comparing HCQ with placebo or other active-comparators for the treatment of knee, hand, or hip OA, extracted data, and performed Cochrane risk of bias assessments. Results: Six RCTs, four in hand OA, two in knee OA, consisting of 842 patients (436 in HCQ arm, 406 in control arm) were included. RCTs were conducted between 2012 and 2020, one each at UK, Netherlands, Germany, Italy, Iran, and Egypt; follow-up period ranged 24 to 52 weeks. High-quality evidence showed no clinically important pain reduction with HCQ compared to placebo/active-control in hand OA (standardized mean difference [SMD], 0.14; 95% confidence interval [CI], –0.20 to 0.48). Effect on pain reduction in knee and hand OA was small and non-significant (SMD, –0.09; 95% CI, –0.44 to 0.25). High-quality evidence showed no improvement in dysfunction with HCQ compared to placebo in hand OA patients (SMD, 0.08; 95% CI, –0.23 to 0.40). Effect on dysfunction improvement in knee and hand OA was modest and statistically non-significant (SMD, –0.20; 95% CI, –0.57 to 0.18). No improvement in quality of life was observed in hand OA. Conclusions: HCQ has no benefit in reducing pain and improving physical function in hand or knee OA patients.
참고문헌 (38)
- "Priority diseases and reasons for inclusion: osteoarthritis" (2014)[URL]
- Haq I, "Osteoarthritis", Postgrad Med J, 79, pp.377~383 (2003)
- World Population to 2300, "United Nations", United Nations, ~ (2004)
- Safiri S, "Global, regional and national burden of osteoarthritis 1990 2017 : a systematic analysis of the Global Burden of Disease Study 2017", Ann Rheum Dis, 79, pp.819~828 (2020)
- "Chronic diseases and health promotion:chronic rheumatic conditions" (2013)[URL]
- Hunter DJ, "Osteoarthritis", Lancet, 393, pp.1745~1759 (2019)
- Prieto-Alhambra D, "Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis : influences of age, gender and osteoarthritis affecting other joints", Ann Rheum Dis, 73, pp.1659~1664 (2014)
- Hunter DJ, "The individual and socioeconomic impact of osteoarthritis", Nat Rev Rheumatol, 10, pp.437~441 (2014)
- Steinmeyer J, "Pharmacological treatment of knee osteoarthritis: special considerations of the new German guideline", Orthop Rev(Pavia), 10, pp.7782~ (2018)
- Ghouri A, "Update on novel pharmacological therapies for osteoarthritis", Ther Adv Musculoskelet Dis, 11, pp.1759720~ (2019)[DOI]
- Hermann W, "Current treatment options for osteoarthritis", Curr Rheumatol Rev, 14, pp.108~116 (2018)
- da Costa BR, "Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis : a network meta-analysis", Lancet, 390, pp.e21~e33 (2017)
- Royal Australian College of General Practitioners, "Guideline for the Management of Knee and Hip Osteoarthritis", Royal Australian College of General Practitioners East Melbourne, ~ (2018)
- McAlindon TE, "OARSI guidelines for the non-surgical management of knee osteoarthritis", Osteoarthritis Cartilage, 22, pp.363~388 (2014)
- Juni P, "Intra-articular corticosteroid for knee osteoarthritis", Cochrane Database Syst Rev, 10, pp.CD005328~ (2015)
- McAlindon TE, "Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis : a randomized clinical trial", JAMA, 317, pp.1967~1975 (2017)
- Haar D, "A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis", Scand J Rheumatol, 22, pp.113~118 (1993)
- Clark P, "Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial", Ann Intern Med, 119, pp.1067~1071 (1993)
- Kyburz D, "Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling", Nat Clin Pract Rheumatol, 2, pp.458~459 (2006)
- Kim HA, "The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes", Arthritis Rheum, 54, pp.2152~2163 (2006)
- Sillat T, "Toll-like receptors in human chondrocytes and osteoarthritic cartilage", Acta Orthop, 84, pp.585~592 (2013)
- Lee W, "Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial", Arthritis Care Res(Hoboken), 70, pp.1320~1325 (2018)
- Kingsbury SR, "Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis : a randomized trial", Ann Intern Med, 168, pp.385~395 (2018)
- Abou-Raya S, "SAT0450 Efficacy of hydroxychloroquine in the treatment of symptomatic knee osteoarthritis in older adults : a randomized placebo-controlled trial", Ann Rheum Dis, 73(Suppl 2), pp.756~757 (2014)
- Saviola G, "Clodronate and hydroxychloroquine in erosive osteoarthritis : a 24-month open randomized pilot study", Mod Rheumatol, 22, pp.256~263 (2012)
- Kroon FPB, "Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis : a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis", RMD Open, 4, pp.e000734~ (2018)
- Singh A, "Efficacy and safety of hydroxychloroquine for the treatment of osteoarthritis : protocol for a systematic review of randomized controlled trials", medRxiv 2020 Jul 26. https:, doi.org, pp.10.1101, 2020.07.20.20157669[DOI]
- Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions" (2019), Wiley-Blackwell
- Higgins JP, "Cochrane Handbook for Systematic Reviews of Interventions" (2019), John Wiley & Sons
- "Handling continuous outcomes in quantitative synthesis. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews" (2013)[URL]
- Singh A, "Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis", J Neurol Sci, 381, pp.347~ (2017)
- Jokar M, "The effect of hydroxychloroquine on symptoms of knee osteoarthritis : a double-blind randomized controlled clinical trial", Iran J Med Sci, 38, pp.221~226 (2013)
- Kedor C, "OP0186 Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands : results of a randomized, double-blind, placebo controlled, multi-centre, investigator-initiated trial(OA TREAT)", Ann Rheum Dis, 79(Suppl 1), pp.115~116 (2020)
- Zhang W, "The placebo effect and its determinants in osteoarthritis : meta-analysis of randomised controlled trials", Ann Rheum Dis, 67, pp.1716~1723 (2008)
- Bannuru RR, "Differential response of placebo treatments in osteoarthritis trials : a systematic review and network meta-analysis", Osteoarthritis Cartilage, 22(Suppl), pp.S24~S25 (2014)
- "Retraction", Ann Rheum Dis, 75, pp.1580~ (2016)
- Dos Reis Neto ET, "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases", Adv Rheumatol, 60, pp.32~ (2020)
- Rempenault C, "Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis: a systematic review", Arthritis Care Res(Hoboken), 72, pp.36~40 (2020)